Coloplast posts Q2 shortfall as DKK 3 billion Kerecis impairment and Medicare change weigh on results
Coloplast A/S recorded a DKK 3 billion impairment against the goodwill of its Kerecis wound-treatment unit after Kerecis reported zero organic growth in the second quarter, which the company attributed to significant sales disruption from a Medicare reimbursement change in the outpatient setting. The medical-device group also set full-year EBIT gro…